This article is more than 5 years old. Information may no longer be current.

Intravitreal triamcinolone can reduce CME in uveitis

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

In patients with uveitic cystoid macular edema, intravitreal triamcinolone can reduce the edema, improve visual acuity and reduce the need for immunosuppressive therapy, according to a retrospective study.

The study, a retrospective noncomparative interventional case series conducted by Howesen Kok, FRCSI, FRCO, and colleagues, included 65 eyes of 54 patients with uveitis-related cystoid macular edema (CME).

The patients were not responding to oral corticosteroids, periocular orbital floor corticosteroid injections or second-line immunosuppressive agents. All were treated with intravitreal injection of 4 mg of triamcinolone.

“The improvement in visual acuity was more significant if the duration of CME before intravitreal triamcinolone was [greater than or equal to] 12 months and if patients were [less than or equal to] 60 years old,” the authors said. “The most important side effect was raised IOP.”

The study is published in the November issue of Ophthalmology.